论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
康复新液联合甲硝唑治疗复发性口腔溃疡的抗炎疗效及症状缓解时间评估
Authors Shen L, Chen X, Zhang T
Received 4 May 2025
Accepted for publication 31 July 2025
Published 29 August 2025 Volume 2025:18 Pages 11925—11934
DOI https://doi.org/10.2147/JIR.S534657
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Ning Quan
Lu Shen,* Xingyue Chen,* Ting Zhang
Department of Stomatology, The General Hospital of Western Theater Command of the Chinese People’s Liberation Army, Chengdu, Sichuan, 610000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ting Zhang, Email zxwu295@163.com
Objective: To evaluate the clinical efficacy and inflammatory modulation potential of Kangfuxin Liquid (KFXY; a traditional Chinese medicine recovery solution) in combination with metronidazole (MTZ) for the treatment of recurrent oral ulcers (ROU).
Methods: A retrospective cohort study was conducted using clinical data from 117 ROU patients admitted between January 2021 and January 2023. Patients were categorized into two groups: a control group (n=58) treated with MTZ oral adhesive patches alone, and an observation group (n=59) receiving KFXY plus MTZ. Primary outcomes included clinical response rates, symptom resolution time (ulcer healing, pain relief, and eating ability), systemic inflammatory biomarkers (C-reactive protein [CRP], tumor necrosis factor-alpha [TNF-α], interleukin-6 [IL-6]), oral microbial flora composition (Veillonella, Streptococcus), and adverse event incidence.
Results: Clinical Efficacy: The observation group demonstrated a significantly higher total response rate (94.92% vs 79.31%; P< 0.05). Symptom Resolution: The KFXY-MTZ combination accelerated ulcer healing (P< 0.05), reduced pain intensity (P< 0.05), and improved oral intake (P< 0.05) compared to MTZ alone. Inflammatory Modulation: Pre-treatment CRP, TNF-α, and IL-6 levels were comparable (P> 0.05); post-treatment, these biomarkers were significantly lower in the observation group (P< 0.05). Microbial Flora: Post-treatment levels of Veillonella and Streptococcus were significantly elevated in the observation group (P< 0.05), indicating potential probiotic effects. Safety: Adverse event rates were similar between groups (control: 5.17%; observation: 6.78%; P> 0.05).
Conclusion: The KFXY-MTZ combination therapy exhibits robust anti-inflammatory and probiotic activities, accelerating ROU healing without compromising safety. These findings support its clinical utility as an integrative treatment strategy for ROU.
Keywords: Kangfuxin liquid, Metronidazole, recurrent oral ulcers, effectiveness, timeliness